Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 35,300,805	$ 28,094,936
Prepaid assets and other current assets	2,258,229	1,092,462
Total current assets	37,559,034	29,187,398
Property and equipment, net	1,102,808
Total assets	38,661,842	29,187,398
Current liabilities:
Accounts payable	1,297,725	410,638
Deferred research grant revenue	24,315
Total current liabilities	1,322,040	410,638
Accrued research and development expense (see Note 5)		1,132,013
Total liabilities	1,322,040	1,542,651
Commitments and contingencies (see Note 4)
Stockholders’ equity:
Common stock; $0.001 par value, 45,000,000 shares authorized; 22,534,874 and 18,450,992 shares issued and outstanding as of December 31, 2020 and 2019, respectively	22,535	18,451
Additional paid-in capital	71,648,453	43,338,710
Accumulated other comprehensive loss	(51,538)
Accumulated deficit	(34,279,648)	(15,712,414)
Total stockholders’ equity	37,339,802	27,644,747
Total liabilities and stockholders’ equity	$ 38,661,842	$ 29,187,398